Restriction Evaluation of Appropriate Carbapenem Therapy (REACT): A Multisite Observational Study
- 23 February 2026
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Technology
- Vol. 42 (3) , 123-129
Abstract
Introduction : Overuse of carbapenem antibiotics can lead to patient harm through adverse effects and further development of bacterial resistance. The purpose of this study was to investigate the sustained impact of meropenem restriction criteria on utilization volume and appropriateness. Methods : A retrospective observational study was conducted to evaluate meropenem restriction criteria among 5 adult hospitals (1 academic hospital and 4 community hospitals) in a single health system. Total meropenem days of therapy/1000 patient days (DOT/1000 PDs) and drug spending was compared before (January 2022) and after implementation (July 2023) were reviewed to investigate total impact of restriction criteria in the first year after implementation. Statistical comparisons used t tests or Mann-Whitney U tests for continuous data and chi square or Fisher’s exact tests for categorical data; significance was defined as P < 0.05. Results : A total of 161 meropenem orders were included in this study, with 61 (39%) found to be inappropriate based on approved restriction criteria. The top 3 reasons for inappropriate meropenem use were undocumented or non-anaphylactic penicillin allergies (31%), lack of qualifying resistant organism within 3 months (26%), and starting meropenem prior to completing 48 hours of empiric therapy with cefepime or piperacillin/tazobactam (23%). The median meropenem DOT/1000 PD decreased from 40.5 to 20 ( P < 0.001). Median monthly drug spend on meropenem across the hospital system decreased by 42% during the study period ( P = 0.001). Conclusions : Meropenem restriction criteria across a multi-site health system can sustainably reduce carbapenem use and associated costs, supporting their continued adoption in antimicrobial stewardship policy.Keywords
This publication has 23 references indexed in Scilit:
- Impact of prolonged carbapenem use-focused antimicrobial stewardship on antimicrobial consumption and factors affecting acceptance of recommendations: a quasi-experimental studyScientific Reports, 2023
- Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2023
- Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network)Clinical Infectious Diseases, 2023
- Adherence to antimicrobial agent recommendations and utilization during drug shortagesAmerican Journal of Health-System Pharmacy, 2022
- Criteria Restricting Inappropriate Meropenem Empiricism (CRIME): a quasi-experimental carbapenem restriction pilot at a large academic medical centreInternational Journal of Antimicrobial Agents, 2022
- Postprescription Review With Threat of Infectious Disease Consultation and Sustained Reduction in Meropenem Use Over Four YearsClinical Infectious Diseases, 2020
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysisInternational Journal of Antimicrobial Agents, 2016
- Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaClinical Infectious Diseases, 2016
- Core Elements of Hospital Antibiotic Stewardship Programs From the Centers for Disease Control and PreventionClinical Infectious Diseases, 2014